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OBJECTIVE—Tissue-speciﬁc self-antigens are ectopically ex-
pressed within the thymus and play an important role in the
induction of central tolerance. Insulin is expressed in both
pancreatic islets and the thymus and is considered to be the
primary antigen for type 1 diabetes. Here, we report the role of
the insulin transactivator MafA in the expression of insulin in the
thymus and susceptibility to type 1 diabetes.
RESEARCH DESIGN AND METHODS—The expression pro-
ﬁles of transcriptional factors (Pdx1, NeuroD, Mafa, and Aire)i n
pancreatic islets and the thymus were examined in nonobese
diabetic (NOD) and control mice. Thymic Ins2 expression and
serum autoantibodies were examined in Mafa knockout mice.
Luciferase reporter assay was performed for newly identiﬁed
polymorphisms of mouse Mafa and human MAFA. A case-control
study was applied for human MAFA polymorphisms.
RESULTS—Mafa, Ins2, and Aire expression was detected in the
thymus. Mafa expression was lower in NOD thymus than in the
control and was correlated with Ins2 expression. Targeted
disruption of MafA reduced thymic Ins2 expression and induced
autoantibodies against pancreatic islets. Functional polymor-
phisms of MafA were newly identiﬁed in NOD mice and humans,
and polymorphisms of human MAFA were associated with
susceptibility to type 1 diabetes but not to autoimmune thyroid
disease.
CONCLUSIONS—These data indicate that functional polymor-
phisms of MafA are associated with reduced expression of
insulin in the thymus and susceptibility to type 1 diabetes in the
NOD mouse as well as human type 1 diabetes. Diabetes 59:
2579–2587, 2010
T
ype 1 diabetes is caused by autoimmune destruc-
tion of insulin-producing -cells of the pancreas
in genetically susceptible individuals (1,2). Sus-
ceptibility to type 1 diabetes is under polygenic
control, with IDDM1 in the major histocompatibility com-
plex (MHC) showing the strongest effect (3). In addition to
MHC-linked susceptibility, the contribution of several non-
MHC genes has been reported (3–6). Most of the non-MHC
genes identiﬁed to date are immune-regulating genes,
which are considered to contribute to type 1 diabetes
susceptibility through impaired regulation of autoimmune
T-cell activation. Among these are genes encoding cyto-
toxic T-lymphocyte antigen 4 (CTLA4) in humans and
mice (7), lymphoid tyrosine phosphatase (PTPN22) (8) in
humans, and Cblb (9) and Ian4 (10) in rats. Most of these
genes are therefore expected to confer susceptibility to
autoimmune diseases in general but not to an autoimmune
disease in a speciﬁc organ, as evidenced by the association
of these genes with not only type 1 diabetes but also other
autoimmune diseases, such as autoimmune thyroid dis-
eases, rheumatoid arthritis, and/or systemic lupus ery-
thematosus (7,11–13).
In contrast to immune-regulating genes conferring sus-
ceptibility to autoimmune diseases through dysregulation
of T-cell activation, genes leading to organ speciﬁcity are
largely unknown, with the only exception being IDDM2
located in the promoter region of the insulin gene (INS).
IDDM2 is most likely to be encoded by a variable-number
tandem repeat (VNTR) polymorphism in the cis-regulatory
region of the insulin gene, which is associated with type 1
diabetes susceptibility through reduced expression of the
insulin gene in the thymus (14–17). Accumulating lines of
evidence indicate that tissue-speciﬁc self-antigens, includ-
ing insulin, are also expressed within the thymus and play
an important role in the induction of central tolerance
(18–20). Abnormality in the regulation of intrathymic
expression of self-antigen is therefore expected to cause
autoimmune disease through impaired negative selection
of antigen-speciﬁc autoreactive T-cells. Since expression
of autoantigens in the thymus is regulated not only by
cis-regulatory elements in the genes encoding self-anti-
gens, as in the case of IDDM2, but also by trans-acting
factors, tissue-speciﬁc transactivators regulating the ex-
pression of self-antigens are important candidate genes for
organ-speciﬁc autoimmune diseases.
MafA has been identiﬁed as an islet-enriched transcrip-
tional activator that binds to the RIPE3b1 element in the
promoter of the insulin gene and has been postulated to
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level in -cells of the pancreas (21,22). Unlike previously
known islet-enriched transcriptional factors, such as Pdx1
and NeuroD/BETA2, which are expressed in non–-cells
as well as in -cells, the expression of MafA is restricted to
only -cells, suggesting that MafA is responsible for tissue-
speciﬁc expression of insulin (23). MafA is therefore an
important candidate among these transcriptional activa-
tors of insulin, leading to organ-speciﬁc autoimmunity to
pancreatic -cells by dysregulation of transcription of
insulin in the thymus as an organ-speciﬁc self-antigen.
Here, we report that MafA is expressed in the thymus and
colocalizes with and modulates the expression of insulin
in the thymus. Functional variants of mouse Mafa and
human MAFA were identiﬁed and found to be associated
with the expression level of insulin in the thymus and
susceptibility to type 1 diabetes.
RESEARCH DESIGN AND METHODS
Female and male nonobese diabetic (NOD)/shi, NOD.nonobese nondiabetic
(NON)-Mhc(H2) congenic (NOD.NON-H2), C3H/He, and NSY mice (24) were
housed under speciﬁc pathogen-free conditions. All experiments were con-
ducted in accordance with the Osaka University Guidelines, which are based
on the National Institutes of Health’s Guide for the Care and Use of
Laboratory Animals. ICR mice with targeted disruption of Mafa (Mafa
knockout mice) were provided by S.T. (25).
Semiquantitative RT-PCR. Pancreatic islets were isolated from four or ﬁve
female NOD.NON-H2 or C3H mice by collagenase digestion, as described
previously (26). To collect insulitis-free pancreatic islets, NOD.NON-H2 mice,
instead of NOD mice, were used for isolation of pancreatic islets for RT-PCR
analysis. Total RNA was isolated from mouse pancreatic islets (at 14–16
weeks old) and thymus (at 3–25 days old) using Isogen (Nippon Gene,
Toyama, Japan) and treated with 10 units RNase-free DNase I (Takara, Shiga,
Japan) to remove genomic DNA. Then, 800 ng total RNA from each sample
was subjected to cDNA synthesis using oligo-dT primers (ReverTra Ace;
Toyobo, Tokyo, Japan) (additional supplementary materials and methods for
this article can be found in an online appendix, available at http://diabetes.
diabetesjournals.org/cgi/content/full/db10-0476/DC1). PCR was performed us-
ing Ex Taq (Takara) within the log phase of the reaction (24–32 cycles).
mRNA levels were measured by nonradioactive RT-PCR and charged-coupled
device imaging, as described previously (27).
Immunohistochemical staining. The thymus was embedded in OCT com-
pound (Tissue-TEC; Miles, Elkhart, IN) and frozen by an acetone–dry-ice
method. Then, 6-m-thick frozen sections were cut with a cryostat, placed on
slides, and ﬁxed in cold acetone for 10 min. The sections were then rinsed in
PBS, incubated for 5 min in 1% Triton X-100, and, after a second rinse,
incubated in diluted serum derived from the same animal as the blocking
serum. The sections were preincubated with 2.4G2 to block the Fc receptor
and incubated for 60 min at room temperature with the ﬁrst antibodies,
washed with PBS, and incubated for 60 min on ice with ﬂuorescein-conjugated
second antibodies. The ﬁrst antibodies were guinea pig anti-porcine insulin
antibody (Dako Japan, Kyoto, Japan), rabbit anti-mouse MafA antibody
(Bethyl Laboratories, Montgomery, TX), and 1:100 diluted sera from Mafa
/
or Mafa
/ mice. Alexa Fluor 488–conjugated anti-rabbit IgG, Alexa Fluor
594–conjugated anti-guinea pig IgG, and Alexa Fluor 488–conjugated anti-
mouse IgG were used as second antibodies. The sections were examined using
a Provis AX80 (Olympus, Tokyo, Japan).
Genomic sequences. Genomic DNA was ampliﬁed by PCR using Takara LA
Taq (Takara). The reﬁned products were subjected to direct sequencing,
utilizing dye termination chemistry with an ABI Prism 3100 Genetic Analyzer
(Applied Biosystems, Tokyo, Japan). To minimize sequencing artifacts, se-
quencing was performed by direct sequencing of the PCR products, with both
strands sequenced at least twice in each strain. The sequences were compared
with the sequence of Mafa from the BALB/c mouse, which was provided by
K.K.
Subjects for molecular scanning and case-control study. A total of 96
unrelated Japanese subjects (16 control subjects, 16 individuals with type 1
diabetes, and 64 individuals with type 2 diabetes) were analyzed for de novo
polymorphisms. One hundred and thirty-eight unrelated Japanese individuals
(53 male and 85 female subjects) with type 1 diabetes, 347 unrelated Japanese
individuals with type 2 diabetes (173 male and 174 female subjects), 190
unrelated Japanese individuals with autoimmune thyroid disease (AITD), and
348 unrelated healthy control subjects were subjected to genotyping. Means 
SD age at onset of type 1 diabetes was 17.4  12.4 years (range 3–59). This
study was approved by the appropriate ethical committees, and informed
consent was obtained from all participants.
Statistical analysis. Allele frequency was estimated by direct counting. The
signiﬁcance of the difference in distribution of alleles was determined by a
Fisher direct probability test. Haplotypes were estimated by the expectation-
maximization algorithm (Haploview version 3.32, four gamete rule [28]).
Statistical analysis for semiquantitative RT-PCR was performed by unpaired t
test. Statistical signiﬁcance was deﬁned as P  0.05.
RESULTS
Putative transcriptional factors of Ins2 in thymus.
Since insulin, a target gene of MafA, is known to be
expressed in both pancreatic islets and the thymus as a
primary antigen in type 1 diabetes (29,30), the expression
proﬁles of Ins1 and Ins2 in mouse pancreatic islets and
neonatal thymus were determined by RT-PCR analysis in
control C3H and NOD mice, a model of type 1 diabetes.
RNA preparations from neonatal thymus contained the
transcript of Ins2 but not Ins1, whereas transcripts of
both Ins1 and 2 were detected in pancreatic islets (Fig.
1A), as shown in previous studies (31,32). To search for
putative transcriptional regulators of Ins2 in the thymus,
several transcription factors that have been reported to
regulate insulin transcription in pancreatic islets and/or
the thymus were also examined by RT-PCR analysis.
Transcripts of Mafa and Aire, but not Pdx1 and Neurod1,
were detected in the thymus, whereas Mafa, Pdx1, and
Neurod1, but not Aire, were detected in the pancreatic
islets (Fig. 1A), indicating a difference in the expression of
insulin transactivators between the thymus and pancreatic
islets.
Reduced expression of Mafa and Ins2 in NOD thymus.
Semiquantitative RT-PCR analyses of Mafa, Ins2, and Aire
were performed on thymic cDNA of NOD and control C3H
mice aged 3–25 days. We found highest expression of Mafa
and Ins2 in the neonatal thymus (3 days of age), and the
expression of both transcripts gradually decreased with
age (Fig. 1B and C). In contrast, Aire showed stable
expression throughout the ages we examined (Fig. 1D). In
mice of all ages (3–25 days) examined, the expression
levels of Mafa and Ins2 were signiﬁcantly lower in the
thymus of NOD mice than in control mice. The largest
differences between NOD mice and control mice were
observed at 3 days of age, both in Mafa (73% reduction,
P  0.0005) and Ins2 (60% reduction, P  0.03) (Fig. 1B
and C). No signiﬁcant difference was observed between
male and female mice (data not shown). In contrast to the
marked difference in Mafa transcript, Aire transcript in
NOD mice was comparable with that in control mice, with
only a slight difference in 3-day-old neonates (28% reduc-
tion, P  0.05) (Fig. 1D). The expression level of Ins2 in
the thymus was strongly correlated with that of Mafa
(R
2 	 0.809) (Fig. 1E). When the data were stratiﬁed by
strain, the correlation was stronger in control (R
2 	 0.863)
than in NOD (R
2 	 0.393) mice. No correlation was found
between Ins2 and Aire in either control C3H (R
2 	 0.145)
(Fig. 1F) or NOD (R
2 	 0.135) mice.
Mafa regulates Ins2 transcription in thymus. To dem-
onstrate the direct effect of MafA on insulin expression in
the thymus, the expression of Mafa and Ins2 in the thymus
was studied in Mafa knockout mice. Mafa transcript was
absent in the thymus in homozygous knockout mice
(Mafa
/) and was signiﬁcantly decreased in heterozy-
gous knockout mice (Mafa
/) compared with that in
wild-type littermates (Mafa
/)( P  0.0001, ANOVA) (Fig.
1G). Ins2 transcript in the thymus was signiﬁcantly lower
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wild-type littermates (P 	 0.001, P 	 0.003, respectively)
(Fig. 1H). These data clearly indicate a direct link of Mafa
with Ins2 transcription in the thymus.
Detection of insulin and MafA proteins by immuno-
histochemical analysis. We next investigated the expres-
sion of insulin and MafA protein in the C3H thymus (7 days
old) using immunohistochemical analysis. Insulin-positive
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FIG. 1. Regulation of Ins2 transcription in thymus by Mafa. A: Gene expression of insulin (Ins1 and Ins2) and putative transcriptional factors
of insulin (Mafa, Pdx1, Neurod1, and Aire) in thymus and pancreatic islets by RT-PCR. B–D: Semiquantitative RT-PCR analysis of expression of
Ins2 (B), Mafa (C), and Aire (D) in C3H (f) and NOD () thymus. Relative mRNA levels normalized to HPRT expression were determined. Data
are expressed as means  SE. E: Close correlation of relative expression levels between Ins2 and Mafa expression in thymus. F: No correlation
between Ins2 and Aire expression in thymus. G and H: Mafa directly regulates insulin transcription in thymus. Semiquantitative RT-PCR of Mafa
(G) and Ins2 (H)i nMafa
/,
/, and
/ mice. Relative mRNA levels normalized to HPRT expression were determined. Data are expressed as
means  SE. *P  0.003; ** P  0.001; ***P < 0.0001, ANOVA.
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costained with anti-cytokeratin antibody, suggesting that
the site of insulin expression is medullary thymic epithelial
cells (supplementary Fig. 1A). The thymus was also
costained by anti-MafA antibodies and insulin antibodies;
MafA staining was observed in the cells positive for
insulin, indicating the colocalization of MafA with insulin
in the thymus (Fig. 2A, supplementary Fig. 1B).
Disruption of Mafa induces autoantibodies to pan-
creatic -cells. To examine the direct link between Mafa
expression and autoimmunity against the pancreas, mouse
pancreas was stained with sera from Mafa
/ and
Mafa
/ mice. The cytoplasm of insulin-positive islet cells
was costained with Mafa
/ serum but not with Mafa
/
serum (Fig. 2B), suggesting that Mafa
/ serum contains
autoantibodies against cytoplasmic proteins of pancreatic
-cells. Mouse IgG-positive cells were also detected in the
cells around islets, suggesting that disruption of Mafa may
induce autoantibodies against not only -cells but also
other cells in the pancreas. Autoantibodies against other
endocrine organs, such as thyroid, adrenal, and salivary
gland, were not detected in Mafa
/ serum (supplemen-
tary Fig. 1C).
Mafa variants were identiﬁed in NOD mouse but not
other strains. The entire nucleotide sequence of mouse
Mafa was identical among the control strains (BALB/c,
C3H, and CTS mice) and an animal model of type 2
diabetes (NSY mice) (Fig. 3A and B). Only NOD mice
showed variation in the nucleotide sequence of Mafa
compared with other strains (BALB/c, C3H, CTS, and NSY
mice) (Fig. 3B). Ten single nucleotide polymorphisms
(SNPs), a 1-bp deletion, and two insertions in the promoter
region; one SNP and one 2-bp deletion in the 3
 untrans-
lated region; and one SNP in the 3
 ﬂanking region in the
NOD mouse were newly identiﬁed (supplementary mate-
rials and methods).
Reduced transcriptional activity of Mafa promoter in
NOD mouse. NOD Mafa promoter activity was signiﬁ-
cantly lower than that of wild-type mice by 27% (P 
0.0001, Student t test) (Fig. 3C, upper panel, and D),
indicating that these variants identiﬁed in the Mafa pro-
moter could contribute to the reduced expression of Mafa
in NOD mice. When an interval between ClaI( AT/CGAT,
1,263 bp upstream of the transcription start site) and SﬁI
(GGCCACTT/GGGCC, 399 bp) sites was removed from
mMafa-p-luc (mMafa-p-lucClaI-SﬁI) (Fig. 3C, lower
panel), the promoter activity appeared to be comparable
between NOD and control mice (Fig. 3E), indicating the
importance of the sequence between the ClaI and SﬁI sites
in the regulation of Mafa transcription.
Identiﬁcation of variants in human MafA gene
(MAFA). The complete MAFA gene in 16 unrelated pa-
tients with type 1 diabetes, 16 unrelated control subjects,
and 64 unrelated patients with type 2 diabetes was
sequenced. In total, 18 SNPs, ﬁve insertions/deletions,
and VNTRs were newly identiﬁed (Genebank accession
no. AB205138) (supplementary materials and methods
Fig. 4A).
The effect of two polymorphisms with a potential func-
tional alteration, an SNP with an amino acid substitution
(1377G/T, Gly346Cys), and 69VNTR in the 5
untranslated
region (UTR) on the expression and function of MAFA was
studied. Luciferase reporter plasmid containing the MAFA
response element (MARE) in the promoter region (3 
MARE/RBGP-luc [33]) was transfected into NIH3T3 ﬁbro-
blast cells (PT67 cells), together with the expression
plasmid for hemagglutinin (HA)-tagged MAFA-Gly346 (HA-
MAFA-Gly346) or HA-tagged MAFA-Cys346 (HA-MAFA-
Cys346). HA-MAFA-Gly346 and HA-MAFA-Cys346 were
conﬁrmed to be expressed and phosphorylated at similar
levels in the cell lysates by Western blotting, using anti-HA
antibody (Fig. 4B). HA-MAFA-Gly346 showed a 23% reduc-
tion of promoter activity compared with HA-MAFA-Cys346
(P  0.003, Student t test) (Fig. 4C), indicating that the
346Cys allele has higher transcriptional activity. The effect
of 69VNTR on MAFA transcription was also assessed by
luciferase assay. Luciferase reporter plasmids containing
the cytomegalovirus (CMV)-hMAFA promoter (CMV-
hMAFA-p-luc) (Fig. 4D) with each allele of 69VNTR (1R,
2R, or 3R) were transfected into TEC1C6 cells (a thymic
medullary epithelial cell line). The allele with one repeat of
the VNTR motif (1R) showed signiﬁcantly higher promoter
activity than the allele with two repeats (2R allele) (P 
0.0001, ANOVA) (Fig. 4E). An allele with three repeats (3R
allele) showed signiﬁcantly lower promoter activity than
the 2R allele (P  0.0001). A similar tendency was ob-
served in Min6 cells (a pancreatic -cell line) with trans-
fection of luciferase reporter plasmids containing hMAFA-
p-luc (1R vs. 2R: P  0.0001; 2R and 3R: P  0.005)
(supplementary Fig. 3).
Gly346Cys was signiﬁcantly associated with susceptibil-
ity to type 1 diabetes, with a signiﬁcantly lower frequency
of the Cys allele in type 1 diabetic than in control subjects
(1.8 vs. 5.1%; odds ratio [OR] 0.34 [95% CI 0.13–0.85], P 	
0.0222) (supplementary Table 1), suggesting that Cys346 of
MAFA, which showed higher transcriptional activity than
FIG. 2. Immunohistochemical staining of thymic medulla. A: Colocal-
ization of insulin and Mafa in thymic medulla (C3H female, 7 days old).
Nuclear staining by DAPI (4,6-diamidino-2-phenylindole) (a), anti-
insulin antibody (b), anti-Mafa antibody (c), and merged image (d).
Bar scale represents 10 m. B: Anti–-cell antibodies in serum of
Mafa
/ mouse. Mafa
/ serum (left panel) and Mafa
/ serum (right
panel) were used as ﬁrst antibodies (Alexa Fluor 488, green). Nuclear
staining (DAPI, blue). Anti-insulin antibody (Alexa Fluor 594, red).
Bar scale represents 100 m. (A high-quality digital representation of
this ﬁgure is available in the online issue.)
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Whereas homozygotes with Cys346 were absent from both
case and control subjects, heterozygotes with Cys346 were
negatively associated with type 1 diabetes (0.33 [0.13–
0.83], P 	 0.0196) (supplementary Table 1), suggesting a
dominant mode of protection by Cys346. Given the well-
known association of INS (IDDM2) polymorphisms with
type 1 diabetes and insulin expression in the thymus, type
1 diabetic patients were stratiﬁed by INS polymorphism
(patients with the 23HphI
/ genotype, which is associ-
ated with lower transcriptional activity of insulin in the
thymus as high-risk subjects and those with 23HphI
/
as low-risk case subjects). The protective effect of Cys346
was concentrated in patients with high-risk IDDM2 (high-
risk patients versus control subjects, P 	 0.0095, 0.23
[0.08–0.71]) (supplementary Table 2).
The Gly346Cys polymorphism and 69VNTR were in
linkage disequilibrium (D
	1.0), giving rise to three
haplotypes (MAFA-ht1–3) (Table 1 and supplementary
Table 3). A haplotype association study revealed that the
frequency of MAFA-ht3 (1R-Cys) was signiﬁcantly lower in
patients with type 1 diabetes than in control subjects (P 
0.03) (supplementary Table 3). When subjects with type 1
diabetes were limited to the high-risk IDDM2 genotype
(23HphI
/ as high-risk case subjects), the association
was further concentrated (OR 0.23 [95% CI 0.07–0.70], P 	
1080bp
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FIG. 3. Reduced promoter activity of Mafa in NOD mice. A: Localization of sequence variants of Mafa in NOD mice. B: Comparison of Mafa
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(cases with high-risk IDDM1 versus control subjects) did
not affect the association with type 1 diabetes (data not
shown). No association with susceptibility to type 2 dia-
betes was found for MAFA (for Gly346Cys 1.52 [0.85–2.71],
P 	 NS) (supplementary Table 4).
To clarify whether the association of MAFA is limited to
autoimmunity against -cells, an association study with
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performed. The Cys allele frequency of MAFA Gly346Cys
was comparable between subjects with AITDs and control
subjects (3.2 vs. 5.1%, P 	 NS) (Table 2). Among 190
subjects with AITDs, 18 were positive for GAD antibody,
indicating autoimmunity against pancreatic -cells as well
as the thyroid gland in these patients. The frequency of the
disease-protective Cys allele in AITD patients without
anti-islet autoimmunity was similar to that in control
subjects (3.5 vs. 5.1%, P 	 NS), whereas it was similar in
AITD patients with anti-islet autoimmunity and type 1
diabetic patients (0.0 vs. 1.8%, P 	 NS).
DISCUSSION
The organ speciﬁcity of autoimmune disease is caused by
impaired immunological tolerance to tissue-restricted pe-
ripheral antigens. Negative selection of autoreactive T-
cells plays an important role in central tolerance to
peripheral antigens, which are ectopically expressed in the
thymus (34,35). Recent studies strongly suggest that insu-
lin is the primary antigen for type 1 diabetes in humans
(36) and the NOD mouse (37) and that the negative
selection of insulin-speciﬁc T-cells could be impaired in
individuals with type 1 diabetes. The expression level of
insulin in the human thymus is known to be associated
with a regulatory polymorphism in the promoter region of
the INS gene, INS-VNTR (IDDM2) (14,15), whereas such
variants have not been identiﬁed in the NOD mouse. The
present study indicates the existence of an alternative
mechanism regulating ectopic insulin transcription in the
thymus other than Aire and INS-VNTR. Multiple transcrip-
tion factors including Pdx-1, Neurod1, and Mafa are
reported to be involved in -cell–speciﬁc transcription of
insulin (23). Of these transcription factors, only Mafa was
shown to be expressed in the thymus and to be closely
correlated with Ins2 expression, suggesting that Mafa
plays a pivotal role in regulating Ins2 transcription in the
thymus. Targeted disruption of Mafa resulted in a marked
decrease in Ins2 transcription in the thymus, indicating a
direct link of Mafa with Ins2 transcription in the thymus.
MAFA expression was also conﬁrmed in a thymic cDNA
library in humans (supplementary Fig. 4). These results
support our hypothesis that MafA is involved in the
pathogenesis of type 1 diabetes through the expression of
insulin in the thymus and the thymic deletion of insulin-
speciﬁc autoreactive T-cells.
MafA has been shown to be a key molecule regulating
the tissue-speciﬁc expression of insulin in -cells, but its
effect is weak unless it is coexpressed with Pdx1 and
NeuroD/BETA2 (38). The expression level of insulin in the
thymus is 
100-fold lower than that in pancreatic islets,
and it is thought to be sufﬁcient to induce negative
selection of autoreactive T-cells in the thymus. In this
sense, it is reasonable to speculate that MafA, whose
transcriptional activity is modest without coexpression of
Pdx1 and NeuroD/Beta2, can control central tolerance to
the insulin peptide by regulating insulin transcription in
the thymus where Pdx1 and Neurod1 are not expressed. A
series of studies showed that newly established medullary
thymic epithelial cell (mTEC) clones spontaneously ex-
press Ins2 despite the absence of detectable Pdx1 (39),
and the regulation of Ins2 transcription in mTEC clones
was not coordinated with the expression level of Aire (40).
Garcia et al. (41) also demonstrated that Ins2 expression
was detected in the thymus of Pdx1
/ mice as well as
wild-type controls, further supporting our hypothesis of a
Pdx1-independent transcriptional mechanism of insulin in
the thymus.
Several reports (42–45) have shown that the thymic
expression of insulin is Aire-dependent, suggesting an
essential role of Aire in insulin expression in the thymus.
Based on the data of our semiquantitative RT-PCR analy-
sis, the expression level of Aire was not correlated with
that of Ins2 in either NOD (R
2 	 0.135) or control (R
2 	
0.145) C3H thymus, in contrast to the strong correlation
between Mafa and Ins2 (NOD: R
2 	 0.393, C3H: R
2 	
0.863). When the data were restricted to 3-day-old neonatal
animals, the expression of Aire in the NOD thymus was
reduced (P  0.05), and there was a weak correlation
between the expression levels of In2 and Aire in the NOD
thymus (R
2 	 0.516) but not in the control thymus (R
2 	
0.042, data not shown). The insight derived from these
observations is that the expression level of Ins2 in the
control thymus is precisely regulated by Mafa, rather than
Aire, in normal conditions. Taking these results together,
we speculate that insulin expression in the thymus is
turned on by Aire and precisely regulated by MafA in
normal conditions. In the present study, targeted disrup-
tion of Mafa led to reduced expression of Ins2 in the
thymus and induced autoantibodies against the pancreas
including cytoplasmic protein of pancreatic -cells, indi-
cating a direct link between Mafa and autoimmunity
against the pancreas.
TABLE 1
Haplotype association of MAFA with susceptibility to high-risk type 1 diabetes
Haplotype
Polymorphism Frequency
OR (95% CI) P value 69 VNTR 1,377 G/T High-risk case subjects* Control subjects
MAFA-ht1 1R G (Gly) 0.721 0.700 1.11 (0.78–1.53) NS
MAFA-ht2 Non-1R G (Gly) 0.266 0.249 1.10 (0.77–1.57) NS
MAFA-ht3 1R T (Cys) 0.012 0.051 0.23 (0.07–0.70) 0.0089
*High-risk case subjects: type 1 diabetic patients with the high-risk IDDM2 allele (23Hph
/). Fisher direct probability test. NS, not
signiﬁcant.
TABLE 2
Genotype and allele frequencies of MAFA 1,377 G/T in AITDs
Control
subjects
AITD
subjects
OR
(95% CI)
P
value
n 263 190
Genotype
G/G 236 (89.7) 178 (93.7)
G/T 27 (10.3) 12 (6.3) 0.59 (0.29–1.19) NS
Allele
G (Gly) 499 (94.9) 368 (96.8)
T (Cys) 27 (5.1) 12 (3.2) 0.60 (0.30–1.20) NS
Data are n (%), unless otherwise indicated. Fisher exact probability
test. NS, not signiﬁcant.
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several polymorphisms that may affect the function of the
gene, including Gly346Cys in the vicinity of the dimeriza-
tion domain (supplementary Fig. 5) and 69VNTR in the
5
UTR. In vitro studies revealed that the Gly346Cys poly-
morphism is functional, with the Gly allele showing a 23%
reduction in transactivation activity compared with the
Cys346 allele. 69VNTR in the 5
UTR was also functional,
with the number of repeats of VNTRs being negatively
correlated with the promoter activity. Based on a hypoth-
esis-driven association study (46), MAFA-ht4 containing
these two polymorphisms with higher transcriptional ac-
tivity was signiﬁcantly associated with protection against
type 1 diabetes, and the association was especially con-
centrated in cases with the high-risk allele (23HphI
/;
INS-VNTR class I/class I) at the IDDM2 locus. These data
suggest the involvement of gene-gene interaction of MAFA
with INS-VNTR (IDDM2) in type 1 diabetes susceptibility,
possibly due to a common underlying mechanism for both
genes in the disease pathogenesis of type 1 diabetes.
Several non-HLA susceptibility loci for type 1 diabetes
have been mapped in recent genome-wide association
studies in Caucasian populations (47), but markers located
near MAFA were not reported to be associated with type 1
diabetes. One possible explanation may be the difference
in genetic background between Japanese and Caucasian
populations, including IDDM2, the susceptibility allele of
which shows large ethnic differences in frequency.
In the present study, an association of MAFA with type
1 diabetes, but not with AITDs, was observed. Further
analysis revealed that the frequency of the disease-protec-
tive allele in AITD patients without anti-islet autoimmunity
was similar to that in control subjects, whereas the
frequency in AITD patients with anti-islet autoimmunity
was similar to that in patients with type 1 diabetes,
suggesting that MAFA is associated with autoimmunity
against pancreatic -cells but not other endocrine organs.
These data support our hypothesis that MAFA is involved
in autoimmunity speciﬁc to pancreatic -cells but not
other endocrine organs such as the thyroid gland.
In conclusion, the present study demonstrated that
MafA expression in thymic medullary epithelial cells is
closely correlated with that of Ins2, suggesting that the
expression of peripheral-tissue antigens in the thymus is
regulated by antigen-speciﬁc mechanisms. Reduced ex-
pression of Mafa and Ins2 in the NOD thymus could lead
insulin-speciﬁc T-cells to escape negative selection, result-
ing in inﬁltration of insulin-speciﬁc T-cells into pancreatic
islets and the development of type 1 diabetes. This hypoth-
esis is further supported by the association of regulatory
polymorphisms in human MAFA with susceptibility to type
1 diabetes. These data suggest a new concept that varia-
tion in antigen-speciﬁc transcriptional factors plays a
critical role in induction of central tolerance to self-
antigens, in addition to the more generic role played by
Aire.
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